Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men
Authors:
- Nischal Mahaveer ChandNCNischal Mahaveer Chand
- Poornima K. TekumallaPTPoornima K. Tekumalla
- Matt T. RosenbergMRMatt T. Rosenberg
- Albert DobiADAlbert Dobi
- Amina AliAAAmina Ali
- Gregory M. MillerGMGregory M. Miller
- Juan J. Aristizabal-HenaoJAJuan J. Aristizabal-Henao
- Elder GrangerEGElder Granger
- Stephen J. FreedlandSFStephen J. Freedland
- Mark D. KelloggMKMark D. Kellogg
- Shiv SrivastavaSSShiv Srivastava
- David G. McLeodDMDavid G. McLeod
Open Access
Abstract
Prostate cancer represents a significant health risk to aging men, in which diagnostic challenges to the identification of aggressive cancers remain unmet. Prostate cancer screening is driven by the prostate-specific antigen (PSA); however, in men with benign prostatic hyperplasia (BPH) due to an enlarged prostate and elevated PSA, PSA’s screening utility is diminished, resulting in many unnecessary biopsies. To address this issue, we previously identified a cleaved fragment of Filamin A (FLNA) protein (as measured with IP-MRM mass spectrometry assessment as a prognostic biomarker for stratifying BPH from prostate cancer and subsequently evaluated its expanded utility in Caucasian (CA) and African American (AA) men. All men had a negative digital rectal examination (DRE) and PSA between 4 and 10 ng/mL and underwent prostate biopsy. In AA men, FLNA serum levels exhibited diagnostic utility for stratifying BPH from patients with aggressive prostate cancer (0.71 AUC and 12.2 OR in 48 men with BPH and 60 men with PCa) and outperformed PSA (0.50 AUC, 2.2 OR). In CA men, FLNA serum levels also exhibited diagnostic utility for stratifying BPH from patients with aggressive prostate cancer (0.74 AUC and 19.4 OR in 191 men with BPH and 109 men with PCa) and outperformed PSA (0.46 AUC, 0.32 OR). Herein, we established FLNA alone as a serum biomarker for stratifying men with BPH vs. those with high Gleason (7–10) prostate cancers compared to the current diagnostic paradigm of using PSA. This approach demonstrates clinical actionability of FLNA alone without the requirement of prostate volume measurement as a test with utility in AA and CA men and represents a significant opportunity to decrease the number of unnecessary biopsies in aggressive prostate cancer diagnoses.Keywords
This publication has 19 references indexed in Scilit:
- The androgen receptor/filamin A complex as a target in prostate cancer microenvironmentCell Death & Disease, 2021
- Benign Prostatic Hyperplasia: A Brief Overview of Pathogenesis, Diagnosis, and Current State of TherapyTechniques in Vascular and Interventional Radiology, 2020
- Prostate-Specific Antigen–Based Screening for Prostate CancerJAMA, 2018
- Diagnosis and Monitoring of Prostatic Lesions: A Comparison of Three Modalities: Multiparametric MRI, Fusion MRI/Transrectal Ultrasound (TRUS), and Traditional TRUSCureus, 2016
- The Prostate Health Index: a new test for the detection of prostate cancerTherapeutic Advances in Urology, 2013
- Applications of transrectal ultrasound in prostate cancerBritish Journal of Radiology, 2012
- Use of the Prostate-Specific Antigen Test among U.S. Men: Findings from the 2005 National Health Interview SurveyCancer Epidemiology, Biomarkers & Prevention, 2008
- Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen StudyEuropean Urology, 2007
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placeboUrology, 1999